Do-Or-Die Time
R&D chiefs agree that big pharma’s fully integrated business model has one more chance to deliver
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
February 21, 2011 Cover
Volume 89, Issue 8
R&D chiefs agree that big pharma’s fully integrated business model has one more chance to deliver
Credit:
R&D chiefs agree that big pharma’s fully integrated business model has one more chance to deliver
The recession behind them, chemical firms plan healthy increases in R&D and capital spending this year
Number and influence of English-language chemistry publications from China climb
Producing photovoltaic panels more sustainably will require reducing energy consumption, toxic substances
More credit and a high interest in fertilizers spurred chemical acquisitions in 2010
Legislation could help the patent office reduce a massive backlog of applications
Stopping degradation of outdated RNA helps staph-infected mice survive